Terumo Neuro (formerly MicroVention) announced today that it received FDA premarket approval (PMA) for its Carotid Stent ...

Ischemic stroke remains one of the leading causes of death and long-term disability worldwide, with narrowing of the carotid ...

European research led by University College London (UCL), together with Amsterdam UMC and the University of Basel, shows that ...

A case study on intravascular lithotripsy for the treatment of calcified carotid disease to demonstrate technical feasibility ...

Terumo Neuro, a global leader in neurovascular innovation and a wholly owned subsidiary of Terumo Corporation, today announced that their Carotid Stent System has received Premarket Approval (PMA) ...

If the lesion involves the CCA and the ICA, the stent has to cover the carotid bifurcation completely. Flow disturbances in the ICA occur if the stent is positioned in the bulb. [9] In our ...

Terumo Neuro, a wholly owned subsidiary of Terumo Corporation, announced that the company’s dual-layer micromesh carotid st ...

First Dual-Layer Micromesh Carotid Stent Approved for Use in the U.S. ALISO VIEJO, Calif., April 15, 2025 /PRNewswire/ -- Terumo Neuro, a global leader in neurovascular innovation and a wholly ...

Ischemic stroke remains one of the leading causes of death and long-term disability worldwide, with narrowing of the carotid artery due to atherosclerosis contributing to up to 30% of all cases.